Sanofi

News

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.

News

Are RSV shots next in line for restrictions in the US?

After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.

News

Sanofi's Paris HQ raided in tax fraud probe

Sanofi's headquarters in Paris has been raided as part of an investigation into a financing deal, said to be related to a historical acquisition.

R&D

Knowledge Quarter, King's Cross, London, UK

From physics to pharma: How Aqemia is reinventing the future...

The UK life sciences sector has long been a crucible for innovation, blending academic excellence with a thriving ecosystem of biotech and pharmaceutical enterprises.

News

Sanofi's type 1 diabetes drug poised for EU rollout

Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes.

Patients

teenager with insulin injector on her bed with teddy bears

World Diabetes Day: Type 1 diabetes in the spotlight and und...

This World Diabetes Day, Sanofi UK and DigiBete are hosting a pop-up event in Leeds to spotlight type 1 diabetes and the need for early detection.

Sanofi gets double blow for MS drug tolebrutinib

Are RSV shots next in line for restrictions in the US?

Sanofi's Paris HQ raided in tax fraud probe

From physics to pharma: How Aqemia is reinventing the future...

Sanofi's type 1 diabetes drug poised for EU rollout

World Diabetes Day: Type 1 diabetes in the spotlight and und...

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Sanofi

Editor's Picks